Category | Patients without dose escalation | Patients with dose escalation |
---|---|---|
Results are shown as No (%) unless stated otherwise. | ||
Patients in study at week 22 | 220 | 109 |
Average duration of follow-up (weeks) | 31.9 | 31.7 |
Average exposure (weeks) | 31.0 | 30.6 |
Patients with one or more adverse event | 160 (72.7) | 77 (70.6) |
Patients who discontinued study agent because of one or more adverse event | 7 (3.2) | 6 (5.5) |
Patients with one or more serious adverse event | 19 (8.6) | 14 (12.8) |
Patients with one or more infection | 80 (36.4) | 39 (35.8) |
Patients with one or more serious infection | 5 (2.3) | 2 (1.8) |